Licochalcone A up-regulates of FasL in mesenchymal stem cells to strengthen bone formation and increase bone mass

Leiguo Ming1,3,4*, Fang Jin5*, Ping Huang6*, Hailang Luo3,4, Wenjia Liu2,3,4, Leilei Zhang3,4, Wei Yuan3,4, Yongjie Zhang1,2,3 & Yan Jin1,2,4

1State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China, 2Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi’an, Shaanxi 710032, China, 3State Key Laboratory of Military Stomatology, Department of Oral Histology and Pathology, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi 710032, China, 4Institute for Tissue Engineering and Regenerative Medicine Research of Xi’an, Xi’an, Shaanxi, China, 5Department of Orthodontics, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi, China, 6Department of Clinical Laboratory, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi, 710032, China.

The role of bone marrow-derived mesenchymal stem cells (BMSCs) in the pathogenesis and therapy of osteoporosis has drawn increasing attention in recent years. In the development of osteoporosis, it has been demonstrated that many changes occurred in the behavior of BMSCs. For example, the biological system of FasL pathways mediated differentiation of ERK and GSK-3β-catenin pathway was damaged. Here we found that 0.35 mg/L Licochalcone A (L-A) had a strong effect in increasing the osteogenic differentiation and mineralization of BMSCs both in vivo and in vitro by up-regulating FasL and further playing a role in regulating the ERK and GSK-3β-catenin systems. It has also demonstrated that the administration of L-A could restore the biological function of the damaged BMSCs differentiation by recovering or protecting bone mass in a disease state through activating the endosteal bone formation and partially inhibiting bone resorption in acute estrogen deficiency model. Results of our study suggested that careful titration of MSC was response to L-A and up-regulated FasL pathways mediating differentiation of ERK and GSK-3β-catenin biological systems under disease state in vivo, restore the impaired function, is one of the ways of L-A relieve or treatment osteoporosis.

Osteoporosis is a bone metabolism disease characterized by the loss of bone microarchitecture thus increasing the risk of bone fractures. The role of BMSCs in the pathogenesis and therapy of osteoporosis has drawn increasing attention in recent years. FAS ligand (FasL) which binds to the Fas receptor is a transmembrane protein that belongs to the TNF family. It represents important apoptotic signaling in many cell types and the pathway of FasL-mediated FAS death has been extensively investigated in the interplay between immune cells, cancer cells and MSC-based immunomodulation. Previous studies also showed that reduced osteoclast apoptosis might contribute to the osteoporotic phenotype and the administration of estrogen could up-regulate the FasL expression in osteoblasts to induce increased osteoclast apoptosis.

Recent studies also showed that FasL promoted the proliferation of human BMSCs, inducing the phosphorylation of ERK1/2 in BMSCs downstream; thus concluded that the ERK1/2-dependent mechanism might be one of the pathways through which BMSCs maintained a stem cell phenotype. ERK could inactivate the expression of GSK-3β resulting in an up-regulation of beta-catenin. The phosphorylation of GSK-3β achieved by ERK binding to it leads to the inactivation of GSK-3β. Thus the expression of β-catenin is increased in the cytoplasm and then it translocate to the nucleus interacting with Tcf/Lefan and further leading to a series reactions. So the function of ERK and GSK-3β-catenin relationship might be an important regulator in BMSCs.

During the process of aging, especially for postmenopausal females, BMSCs in bone marrow shift to adipocyte gradually with a reduction of osteogenesis and bone formation, finally resulting in osteoporosis. In this process, many changes occurred in the behavior of BMSCs such as self-renewal and differentiation ability in addition to cell proliferation, differentiation, cell cycle phases (depending on gene modification) and the production of cytokine and growth factors. Our team previously found that the osteogenic differentiation of BMSCs from estrogen deficiency rats with osteoporosis was decreased while the adipogenic differentiation was increased.
compared with normal BMSCs. We also found that FasL significantly decreased and ERK and GSK-3β-catenin biological systems changed in BMSCs in the same model.

Some drugs, such as PTH, Bisphosphonates and vitamin D have been used in clinic to stimulate bone formation in osteoporosis patients. However, long-term trials showed that these drugs had no effect in preventing hip fracture. What was more, side-effects such as hypercalcemia, nausea and diarrhea also happened in the long-term observation. However, whether BMSCs respond to those drugs in vivo was unclear. As there is a growing consensus that regulating the behavior of BMSCs could increase bone formation, in this study we tried to use small molecular compounds to reverse the abnormal function of BMSCs, aiming to establish a new strategy to relieve or treat osteoporosis. Licorice, one of the most commonly used herbs in traditional medicine, Licochalcone A (L-A) derives from licorice. It has been proven to have the ability of anti-inflammatory, anti-parasitic and anti-browning, and regulating bone metabolism. Pharmacological activity of L-A has been broadly studied, but the molecular mechanism is not particularly clear, especially on the differentiation of BMSCs. In this study, we tried to investigate whether L-A has an effect on the osteogenic differentiation of BMSCs in vivo and in vitro. Results indicated that L-A could up-regulate the FasL expression and affect the ERK and GSK-3β-catenin pathway to rescue the differentiation disorder of osteoporotic BMSCs, suggesting a potential therapeutic strategy for osteoporosis as well as bone regenerative medicine.

**Results**

**Effects of L-A on the osteogenic differentiation of BMSCs.** Flow-cytometry analysis showed that BMSCs highly expressed SCA-1, CD29, CD90, CD105 and CD106 while they did not express CD34 and CD45 (Figures not show). We screened different doses of L-A in the procedure of the osteogenic differentiation of BMSCs to choose the optimal dose. L-A at low concentration of 0.035 mg/L had minimal effect on the osteogenic differentiation of BMSCs, whereas higher concentration of 35 mg/L would inhibit BMSCs differentiation. L-A at the concentration ranged of 3.5 mg−0.035 mg/L would improve BMSCs osteogenic differentiation. And the 0.35 mg/L was the optimal dose which could significantly improve the osteogenic differentiation. Under this concentration, Real-time PCR showed that osteogenic marker Collα1, OCN, Runx-2 and OSX mRNA were significantly increased in L-A treated BMSCs group (Fig. 1.b). Clearly, 0.35 mg/L is the optimum concentration for L-A and this study would carry out under this concentration. Further study revealed that treatment of L-A increased both alkaline phosphate (ALP) stained positive colonies and alizarin red stained mineralized nodules in BMSCs that differentiated into osteoblasts as well as the quantitative ALP activity at day 7, 14 and the volume of calcium sediment yield at day 21 of osteogenic induction (Fig. 1.c). Osteogenic marker Collα1, OCN, Runx-2 and OSX mRNA were also detected at day 7 and day 14, L-A significantly improved the BMSCs osteogenic differentiation in osteo-inducing medium (Fig. 1.d). L-A was also administered in the group of OVX-BMSCs and Aging-BMSCs and the same tendency was observed with previous results (Supplementary Fig. 1. a, b; Supplementary Fig. 1. a, b). These results indicated that 0.35 mg/L L-A had a pronounced ability to enhance BMSCs osteogenic differentiation and mineralization. To further confirm the role of L-A regulated FasL in BMSCs, we tested whether FasL knockdown in BMSCs rescued the function of L-A. The RT-real time PCR results showed that separate knockdown of FasL decreased the effect of L-A up-regulated MSCs (Supplementary Fig. 7. a). Notably, western blot revealed that the knockdown of FasL decreased the effect of L-A up-regulated MSCs protein level (Supplementary Fig. 7. b), suggesting that L-A up-regulated in the BMSCS functioned through their target gene FasL.

The mechanism of L-A regulating the osteogenic differentiation of BMSCs. A number of factors and signaling pathways have important roles in the differentiation and stemness maintenance of BMSCs. Factors including BMP-2, PGF, IGF, Runkld/OPG, Fas/FasL and signaling pathways including Mapks, Wnt, Notch1, Nos, Oct4 were reported to participate in the BMSCs differentiation. To investigate the mechanism of L-A regulating BMSCs osteogenic differentiation, we performed Real-time PCR to study the possible genes which may participate in the procedure. Results showed that the expression level of FasL, target gene of Mapk signaling and β-catenin was significantly up-regulated while the expression of GSK-3β was down-regulated (Fig. 2.a). To further confirm the results of real time PCR, results of western blot revealed that the protein expression of FasL, phosphorylation ERK1/2 and active-β-catenin was significantly up-regulated while GSK-3β was down-regulated at the day of 3, 7 and 14 (Fig. 2.b) than control group (OS-C group). This phenomenon was observed both in BMSCs planted in normal cultural medium (L-A group) and osteo-inducing medium (OS-L-A group) which were administrated with L-A. In addition, we also measured gene expression level of FasL, ERK1/2, catenin and GSK-3β at the day of 3, 7 and 14 and results had the same tendency with results in protein level (Fig. 2.c). It was worth noting that the protein and gene expression levels of Runx-2 were stronger in OS-L-A group than that in OS-C group (Fig. 2.b, c).The same tendency was observed with those results in OVX-BMSCs and Aging-BMSCs groups too (Supplementary Fig. 1.c, d; Supplementary Fig. 2.c, d). These results suggested that L-A could stimulate the osteoblastic differentiation of BMSCs by up-regulating the expression of FasL, phosphorylation ERK1/2, inactivated GSK-3β and activated-β-catenin.

**Treatment with L-A partially recovers loss of trabecular bone and increases endosteal bone formation in OVX rats.** To determine whether L-A could recover bone mass in a disease state, we treated 8-week-old ovariectomized (OVX) rats with PBS or L-A 12 weeks after OVX (Fig. 3.a). OVX model was evaluated by micro CT, results revealed that the trabecular bone volume/total volume (BV/TV) and bone mineral density (BMD) were decreased and trabecular separation (Tb.Sp) was increased than Sham group (Fig. 3.b). TRAP/ALP staining results showed that the endosteal bone formation in trabecular bone in L-A treated group was increased (the black arrows indicated ALP positive) and the TRAP staining was weakly positive (the green arrows indicated) than OVX group. There was no difference in the same group between different time points over 4, 8 and 12 weeks (Fig. 3.c). At each time point, femur bone mass was also detected by micro CT and results indicated that L-A could partially recover the loss of trabecular bone (Fig. 3.d) by means of inducing a higher distal femoral trabecular bone volume (BV/TV) and bone mass (Fig. 3.f). The calcinfluenrescent labeling of the newly formed bone observed at 4, 8 and 12 weeks (Fig. 3.e) demonstrated the same tendency. Test of loading with a maximum load to the femur and fifth lumbar vertebral bodies (LVB) was also carried out in L-A group, OVX group and Sham group treated with PBS. Results also indicated that L-A group had a stronger potent of anti-pressure load than OVX group, no difference with statistical significance was found between L-A and Sham group (Fig. 3h, i).These data suggested that L-A could activate endosteal bone formation which nearly had the same characteristic of bone tissues in normal state in acute estrogen deficiency model and increase bone mass.

**Treatment with L-A partially prevents trabecular bone loss and increases endosteal bone formation in OVX rats.** To determine whether L-A could prevent trabecular bone loss in a disease state, we treated 8-week-old OVX rats with PBS, L-A 3 days after OVX (Fig. 4.a). OVX model was evaluated by micro CT, after ovariectomized 3 days, BV/TV, BMD and Tb.Sp was detected, there is no difference between Sham group and OVX (Fig. 4.b).
The TRAP/ALP staining results showed that the TRAP positive (the green arrows indicated) is increased and ALP positive (the black arrows indicated) was decreased in OVX group at over time of 4, 8 and 12 weeks; but TRAP weakly positive and ALP stronger positive in Sham and L-A treat group at same time point (Fig. 4.c). And femur bone mass also detected by micro CT, L-A could prevent trabecular bone loss (Fig. 4.d), induced a higher distal femoral trabecular bone volume and bone mass to inhibit the bone resorption (Fig. 4.f, g). Compared to the OVX group, L-A could unremitting stimulate new bone formation and partially inhibit bone resorption. The calceinfluorescent labeling of the newly formed bone was also observed at 4, 8 and 12 weeks (Fig. 4.e), with a corresponding greater maximum load of the femur and fifth LVB respectively in L-A group rats treated with L-A compared to OVX and Sham group treated with PBS, L-A 6 weeks after OVX (Fig. 5.a). OVX model was evaluated by micro CT, BV/TV and BMD were decreased and trabecular separation (Tb.Sp) was significantly increased than Sham group (Fig. 6.b). OVX rats were treated by L-A once a day, a week later, isolated BMSCs from L-A treated, Sham, OVX group rats and performed analysis at the first passage. Proliferation assay (cell clone and MTT assay) showed no difference between L-A treated rats BMSCs and Sham BMSCs, but significantly higher than OVX BMSCs (Fig. 5.b). Osteogenic differentiation assay showed OVX BMSCs formed less ALP positive clone and mineralized nodules after osteogenic induction than L-A treated rats BMSCs and Sham BMSCs, in accordance with ALP activity and volume of calcium sediment yield, respectively. Real-time PCR showed that osteogenic marker Col1a1, OCN, Runx-2 and OSX mRNA expression were no significantly difference between L-A treated rats BMSCs and Sham BMSCs, but significantly higher than OVX BMSCs (Fig. 5.c). Western blot revealed that the protein of FasL, phosphorylation ERK1/2 and active catenin in L-A treated rats BMSCs and Sham BMSCs is significantly up-regulated and GSK-3b is significantly down-regulated than OVX BMSCs at day7, but no difference between L-A treated rats BMSCs and Sham BMSCs. In addition, we also measured gene expression level of the FasL, ERK1/2, catenin and GSK-3b. It has the same point and tendency with the protein expression level (Fig. 5.d). These results suggested that BMSCs was response L-A in vivo, up-regulated FasL, enhanced phosphorylation ERK1/2, inactivated GSK-3b and activated catenin to restore the biological function of the damaged BMSCs.

The effects of L-A on the BMSCs proliferation and differentiation in osteoporosis state. The osteogenic differentiation potential of BMSCs from estrogen deficiency induced osteoporosis rats was decreased and L-A could recover the potent of BMSCs osteogenic differentiation in vitro (Supplementary Fig. 1.). To determine whether L-A could effects BMSCs proliferation and differentiation in the osteoporosis state, we treated 8-week-old OVX rats with PBS, L-A 6 weeks after OVX (Fig. 5.a). OVX model was evaluated by micro CT, BV/TV and BMD were decreased and trabecular separation (Tb.Sp) was significantly increased than Sham group (Fig. 6.b). OVX rats were treated by L-A once a day, a week later, isolated BMSCs from L-A treated, Sham, OVX group rats and performed analysis at the first passage. Proliferation assay (cell clone and MTT assay) showed no difference between L-A treated rats BMSCs and Sham BMSCs, but significantly higher than OVX BMSCs (Fig. 5.b). Osteogenic differentiation assay showed OVX BMSCs formed less ALP positive clone and mineralized nodules after osteogenic induction than L-A treated rats BMSCs and Sham BMSCs, in accordance with ALP activity and volume of calcium sediment yield, respectively. Real-time PCR showed that osteogenic marker Col1a1, OCN, Runx2 and OSX mRNA expression were no significantly difference between L-A treated rats BMSCs and Sham BMSCs, but significantly higher than OVX BMSCs (Fig. 5.c). Western blot revealed that the protein of FasL, phosphorylation ERK1/2 and active catenin in L-A treated rats BMSCs and Sham BMSCs is significantly up-regulated and GSK-3b is significantly down-regulated than OVX BMSCs at day7, but no difference between L-A treated rats BMSCs and Sham BMSCs. In addition, we also measured gene expression level of the FasL, ERK1/2, catenin and GSK-3b. It has the same point and tendency with the protein expression level (Fig. 5.d). These results suggested that BMSCs was response L-A in vivo, up-regulated FasL, enhanced phosphorylation ERK1/2, inactivated GSK-3b and activated catenin to restore the biological function of the damaged BMSCs.
BMSCs treated by L-A augments bone formation in OVX rats. The osteogenic differentiation of BMSCs from estrogen deficiency induced osteoporosis rats was decreased and L-A could recover the potent of BMSCs osteogenic differentiation function in vitro (Supplementary Fig. 1.). Here we performed a homo transplantation study. We intravenously injected L-A treated OVX-BMSCs, OVX-BMSCs, L-A treated Sham-BMSCs, Sham-BMSCs in OVX and Sham rats 6 weeks after surgery (Fig. 6.a). OVX model was evaluated by micro CT, BV/TV and BMD was decreased and trabecular separation (Tb.Sp) was significantly increased than Sham group (Fig. 6.b). At 4 weeks and 8 weeks after injection, TRAP/ALP staining results showed that the positive TRAP staining (the green arrows indicated) was more significant in OVX and OVX-BMSCs injection groups while positive ALP staining (the black arrows indicated) was decreased in this two groups at the same time point. In accordance, TRAP staining and ALP staining in Sham, L-A treated OVX and Sham BMSCs, normal BMSCs injection groups showed an opposite trend at the same time points (Fig. 6.c). The femur bone mass was also detected by micro CT. We observed that OVX-BMSCs injection could not recover the loss of trabecular bone compared with the OVX group; however the newly formed bone tissues in L-A treated OVX-MSCs injection group was nearly the same with normal BMSCs injection group compared OVX injection PBS negatively control, though a little lower than that of Sham injection PBS group. Newly formed bone tissues in L-A treated normal BMSCs group were a little higher than that of Sham injection PBS, but the difference was not statistically significant. Calceinfluorescent labeling of the newly formed bone tissues was observed at 4, 8 weeks (Fig. 6.d) and the distal femoral trabecular BV/TV and BMD were also analyzed, results were in accordance with that mentioned above (Fig. 6.e, f). Test of maximum load to the femur and fifth LVB was carried out respectively in six groups. L-A treated OVX-MSCs injection OVX rats group, normal BMSCs injection OVX rats group had a stronger potent of anti-pressure load than OVX injection PBS and OVX-MCS injection OVX rats group, no difference with statistical significance was observed between Sham injection PBS and L-A treated normal BMSCs injection Sham group (Fig. 3g, h). These results suggested that L-A treated OVX-BMSCs could activate endosteal bone formation and increase bone mass. Thus L-A could restore the biological function of the damaged BMSCs to perform like normal ones.

Discussion

BMSCs within bone marrow have a multi-lineage potential and give rise to the following cell types: osteoblasts, chondrocytes and adipocytes30–31. BMSCs under going osteogenic differentiation in the bone marrow32–33 and the osteoblastic progenitors mobilizing to the bone surface area crucial steps in osteoblast maturation and forming of mineralized tissues34–35. But during the process of aging, especially for postmenopausal females, BMSCs in bone marrow shift to adipocyte gradually with a reduction of osteogenesis and bone formation, thus finally resulting in osteoporosis15, 19. In such a circumstance, many changes occurred in the behavior of BMSCs including self-renewal and differentiation ability in addition to cell proliferation, cell cycle phases and production of cytokine and growth factors16–18. In this study we tried to use a small molecular compound to reverse the abnormal function of BMSCs aiming to establish a new strategy to treat osteoporosis. Data showed that 0.35 mg/L L-A had a pronounced ability to enhance BMSCs osteogenic differentiation and mineralization by up-regulating FasL, enhancing phosphorylation ERK1/2, active catenin, phosphorylation GSK-3b and Runx-2 with the time course of day 3, 7 and 14. So we concluded that L-A could recover or protected bone mass in a disease state by activating endosteal bone formation and partially inhibiting bone resorption. And its effect was comparable to bone formation in rats in the normal state in acute estrogen deficiency model. Test of isolated L-A treated OVX rats BMSCs indicated that they were responsible to L-A in vivo through ERK and GSK-3b-catenin pathway by which to restore the biological function of the damaged BMSCs.

Figure 2 | The molecule mechanism of L-A was regulated BMSCs osteogenic differentiation. (a) BMSCs differentiation related factors and signal pathways target gene screening by RT-real time PCR. (b) To further confirm the results of RT-real time PCR, western blot revealed that the protein of FasL, phosphorylation ERK1/2, active catenin, phosphorylation GSK-3b and Runx-2 with the time course of day 3, 7 and 14. (c) Measured gene expression level of the FasL, ERK1/2, Catenin, GSK-3b and Runx-2 at the over time of day 3, 7 and 14. Key: n = 6 per group. *P < 0.05, **P < 0.01 compared to the OS-C group. All data are shown as the mean ± s.d.
BMSCs. Further study found that OVX-BMSCs from injection of L-A treatment group realized the same function recovery. So BMSCs response to L-A under disease state in vivo and recovering the impaired function was part of the possible mechanisms of L-A treating osteoporosis.

To further clear the relationship of L-A regulating FasL and BMSCs, Rodrigues et al. found that Fas, the receptor for FasL, was expressed during the procedure when MSC differentiated into osteoblasts, and continued to die significantly like undifferentiated MSC, emphasizing the need for continued protection of MSC differentiating into bone cells. Exogenously adding low level of FasL would promote proliferation of bone marrow-derived mesenchymal stem cells while higher levels inhibited their differentiation into adipocytes. Previous studies showed that L-A can promote bone metabolism, promote osteoblast osteogenic differentiation inhibit osteoclast resorption. In this study, L-A significantly increased the expression of FasL, but no change in the expression of Fas was observed in BMSCs. We also found that decreasing of FasL in OVX-BMSCs led to a weaker cell potential for proliferation and differentiation. When BMSCs from various experimental groups including normal BMSCs, OVX-BMSCs, Aging-BMSCs were treated by L-A, the FasL expression was up-regulated and further enhanced the BMSCs osteogenic differentiation and mineralization. So it was important to maintain the stability of the FasL level or moderately increase its expression so as to keep the balance of proliferation and differentiation of BMSCs. FasL has the ability of promoting the proliferation of BMSCs, inducing the phosphorylating procedure of ERK1/2 and survival in up-regulation in BMSCs. And it was through ERK1/2-dependent mechanisms that BMSCs maintain stem cell phenotype.

Figure 3 | Treatment with L-A partially recovers trabecular bone and increases endosteal bone formation in OVX rats. (a) Diagram of the study and treatment methods. (b) Trabecular bone volume (BV)/tissue volume (TV), bone mineral density (BMD) and trabecular separation (Tb.Sp) were detected by micro-CT and evaluated OVX rat model. (c) TRAP/ALP staining the section samples of non-decalcified trabecular bone (2 μm thick). Black open arrows indicate new bone formation and green open arrows indicate bone resorption Right-Sidedness image Scale bar, 50 μm. (d) Femur bone mass was detected by micro CT, top; and trabecular bone three-dimensional reconstruction in red box, bottom, Scale bar, 500 μm. (e) The calcinefluorescent labeling of the newly formed bone at different time point. Scale bar, 100 μm. (f) TV/BV of Trabecular bone. (g) BMD of Trabecular bone. Greater maximum load of (h) the femur and (i) the fifth lumbar vertebral bodies (LVB) respectively in L-A group rats treated with L-A compared to OVX and Sham group treated with PBS. Key: n = 6 per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the OVX group. All data are shown as the mean ± s.d.
enhance the osteogenic differentiation and mineralization of BMSCs and it would be a new pharmacology molecular mechanism of protecting bone metabolism and regulating bone regeneration. FASL-mediated FAS death pathway has been extensively investigated in the interplay between immune cells, cancer cells and MSC-based immunomodulation. To locate the migration of injected BMSCs, we observed that almost all the GFP-BMSCs were entered the spleen and bone marrow after intravenous injection 24, 48 hours, 7 days and 14 days while vascular walls of liver, heart and lung could only be observed only a few BMSCs; renal tissue was not detected the BMSCs (Supplementary Fig. 3.). As immune function declines under osteoporosis condition, migration of normal BMSCs into spleen and bone marrow might regulate the immune function of OVX-rats and change the microenvironment of bone metabolism, inhibiting osteoclast function and promoting bone formation. In both BMSCs injection and L-A injection treating group, FASL-mediated FAS death pathway had been activated and thus may protect the bone metabolism through regulating the immune function and maintain the balance of osteoblast/osteoclast. We also observed the portion of the BMSCs moved on femoral growth plate and trabecular bone surface in bone marrow. It may be directly involved in the regulation procedure of the inhibition of osteoclast activity, promoting osteoblast bone formation process (Supplementary Fig. 4.White arrows indicate).

In summary, we found L-A could significantly up-regulate the expression of FasL, enhance ERK phosphorylation, making ERK further binding to GSK-3β and phosphorylating it to lead to an inactivation of GSK-3β. As a result, stabilized β-catenin in BMSCs led to enhanced or recovered function of osteogenic differentiation of damaged cells both in vivo and in vitro. The results of our study suggested that careful titration of BMSCs respond L-A in vivo may be a promising avenue for the prevention of osteoporosis or the treatment of its early stages.

**Methods**

**Animals.** All animal procedures were performed according to the guidelines of the Animal Care Committee of the Fourth Military Medical University, Xi’an, China, and all experimental protocols were approved by Fourth Military Medical University. Four-2-week-old female SD rats, Four-24-month-old female SD rats were used to isolate BMSCs. One hundred and ten 8-week-old female SD rats were randomly divided into two groups, and they underwent either sham surgery or bilateral ovariectomy (OVX) under general anesthesia by the dorsal approach. Then all rats were housed under specific pathogen-free conditions (22°C, 12-hour light/12-hour dark-cycles and 50–55% humidity) with free access to food pellets and tap water for 6 months.

**Cell culture.** Primary culture of BMSCs was established as described previously. 2-week-old,24-month-old, OVX/Sham/L-A treated female SD rats were sacrificed by dislocation of the cervical spine. Tibias and femurs were immediately dissected from attached muscles and tissues using aseptic techniques, respectively. Ends of bones were removed, marrow plugs were flushed dispersed by repeated pipetting and cells were forcefully passed through a 19-gauge needle to obtain a single cell suspension. Cells were cultured in growth medium containing a MEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 1% penicillin and streptomycin. The cell suspension was seeded in10-cm tissue culture dishes and grown in the growth medium in a humidified atmosphere of 5% CO2 at 37°C, respectively. The medium was changed every 2–3 days to remove non-adherent cells, and adherent cells were

---

Figure 4 | Treatment with L-A partially prevents trabecular bone loss and increases endosteal bone formation in OVX rats. (a) Diagram of the study and treatment methods. (b) BV/TV, BMD and Tb.Sp were detected by micro CT and evaluated OVX rat model. (c) TRAP/ALP staining the section samples of non-decalcified trabecular bone (2 μm thick). Black open arrows indicate new bone formation and green open arrows indicate bone resorption. Right-Sidedness image Scale bar, 50 μm. (d) Femur bone mass was detected by micro CT, top and trabecular bone three-dimensional reconstruction in red box, bottom, Scale bar, 500 μm. (e) The calcineflourescent labeling of the newly formed bone at different time point. Scale bar,100 μm. (f) TV/BV of Trabecular bone. (g) BMD of Trabecular bone. Greater maximum load of (h) the femur and (i) the fifth lumbar vertebral bodies (LVB) respectively in L-A group rats treated with L-A compared to OVX and Sham group treated with PBS. Key: n = 6 per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the OVX group. All data are shown as the mean ± s.d.
cultured until they were confluent. At confluence, BMSCs were passaged after digestion with 0.25% trypsin/1 mM EDTA.

**ALP activity measured with time course and ALP histochemical staining.** BMSCs were plated in 12-well tissue culture plates. When cells were confluent, osteoinduction medium (10 μM Mnxamethasone, 10 mM b-glycerophosphate and 50 mg/ml ASAP) containing 0.0035 mg-35 mg/L L-A (Sigma-Aldrich, Cat No.S8749-22-7) was changed. Equal volumes of vehicle (DMSO) were used as control. ALP activity was measured after 7 and 14 days (n=6 per group). ALP activity was detected using a commercial kit, as instructed (Nanjing Jiancheng Bioengineering Ltd, Nanjing, China). A modified method of King (Powell and Smith 1954) was used in the kit and results were expressed as nmol phenol/15 min/mg protein. Protein concentrations were determined using a BCA protein assay kit. To further compare the potency of different concentration L-A to stimulate osteogenic differentiation, numbers of colonies positive for ALP were also compared on day 14. Cells were fixed in 3.7% formaldehyde and 90% ethanol solution for 5 min, washed then stained a commercial kit of ALP stain, as instructed (Beyotime Institute of Biotechnology, Shanghai, china). 0.35 mg/L had previously been found to be optimal concentration for L-A, to improve osteogenic differentiation.

**Aliizarin red staining and Calcium deposition measured.** Histochemical alizarinred staining of mineralized cell nodules was carried out on day 21. Briefly, cells were fixed in 3.7% formaldehyde for 10 min and stained in 0.1% alizarin red for 1 h at 37°C. Calcium deposition measurements were performed on day 21 after osteoinduction cultured. Briefly, cultures were rinsed twice in PBS and decalcified for 24 h in 0.1 M HCl; calcium content in HCl supernatant samples was measured using a calcium colorimetric assay kit (Biovision, San Francisco, CA, USA) and results were expressed as mg/dish.

**Real-time RT-PCR of mRNA expression.** Total RNA was separated using Trizol reagent (Invitrogen) according to the manufacturer’s standard instructions. For reverse transcription of mRNA, random-primed cDNA was synthesized from 2 μg total RNA using a Prime Script RT reagent kit (TaKaRa, Dalian, China). Real-time PCR was performed using 2 μl of cDNA product in a 25 μl reaction volume with Premix Ex Taq™II (Takara Biotechnology), specific primers (see below) and 0.35 mg/ml SYBR® Premix Ex Taq™II (Takara Biotechnology). Real-time PCR reactions were performed in triplicate, and results after calibration with GAPDH expression were calculated using the ΔΔCt method and are presented as fold increase, relative to non-stimulated control.

**Western blot analysis.** The western blot analysis was performed as previously described44,45. Whole-cell lysates were extracted with lysis buffer for western blotting. 25 μg proteins were loaded on 10% sodium dodecyl sulfate polyacrylamide gels, transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA) and blocked with 5% nonfat milk powder in PBST (PBS with0.1% Tween), respectively. The membranes were probed overnight with the following primary antibodies. The primary antibody for mouse RUNX2, p-GSK-3b (Abcam, Cambridge, MA, USA), ERK1/2, p-ERK1/2, active-catenin, b-actin (Cell Signaling, Beverly, MA, USA, Fast. (Santa Cruz, Dallas, TX, USA) were used in this study. Then, the membranes were incubated with peroxidase-conjugated secondary antibody (Boster, Wuhan, China). The blots were visualized using an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer’s recommended instructions. The gray values of the blots in the pictures were measured with Image-Pro Plus 6.0 software (Media Cybernetics, Inc. Bethesda, MD, USA). The b-actin as internal control to verify the consistency of the amount of all of the samples, based on this, for each of the detection of the target protein, the expression level of a sample is set to “1”, compare the ratio between the different samples. Repeat the test to verify whether there is a stable protein changes in trends or consistency.

**L-A treatment in vivo.** Three months/days after the ovariectomy (the animal model evaluated by micro CT), the rats were injected intraperitoneally twice a week with 0.35 mg/kg body weight of L-A as the treatment group, also injected Sham and O VX sesame oil (as a vehicle control) for 12weeks. Three days before death, all rats were injected calcein with 10 mg/kg. Three rats were sacrificed every day by dislocation. Three left femurs used to scanning micro CT (Siemens Inveon Micro CT, Germany), then isolated Sham/O VX BMSCs and amplification cultured. The different samples. Repeat the test to verify whether there is a stable protein changes in trends or consistency.

**Response of BMSCs on L-A in vivo.** Ten weeks after the ovariectomy (the animal model evaluated by micro CT), the rats were injected intraperitoneally once a day with 0.35 mg/kg body weight of L-A as the treatment group, also injected Sham and O VX sesame oil (as a vehicle control) for 12 weeks. 7 days later, isolated the BMSCs from Sham, O VX and L-A treated O VX group respectively. Cell proliferation was assayed by the trypan blue staining cell clone and MTT assay as previously described. Cell differentiation was detected by ALP staining and ALP activity measure, Alizarin red staining and Calcium deposition measure, osteogenic marker and signal pathway related mRNA expression were detected by RT-real time PCR. Protein expressions detected by western blot.

**BMSCs treatment in vivo.** Ten weeks after the ovariectomy (the animal model evaluated by micro CT), isolated Sham/O VX BMSCs and amplification cultured. The
second generation of Sham/OVX BMSCs was planted 10-cm tissue culture dishes, half of dish with Sham/OVX BMSCs was treated by L-A. 1 × 10^6 cell/kg body weight intravenous injection, including OVX rats injected by OVX-BMSCs, PBS, L-A treated OVX-BMSCs, normal BMSCs, and Sham rats injected by PBS, L-A treated normal BMSCs. Black open arrows indicate new bone formation and green open arrows indicate bone resorption. Right-Sidedness image Scale bar, 50 μm. (d) Femur bone mass was detected by micro CT, top; and trabecular bone three-dimensional reconstruction in red box, middle, Scale bar, 300 μm. The calceinfluorescent labeling of newly formed bone at different time point, bottom, Scale bar, 100 μm. (e, f) TV/BV and BMD of Trabecular bone after treated 4 and 8 weeks. Greater maximum load of (g) the femur and (h) the fifth lumbar vertebral bodies (LVB) respectively in OVX/Sham group rats treated with kinds BMSCs. Key: n = 6 per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the OVX group. All data are shown as the mean ± s.d.

Figure 6 | BMSCs treated by L-A augments bone formation in OVX rats. (a) Diagram of the study and treatment methods. (b) BV/TV, BMD and Tb.Sp were detected by micro-CT and evaluated OVX rat model. (c) TRAP/ALP staining the section samples of non-decalcified trabecular bone (2 μm thick) including OVX rats injected by OVX-BMSCs, PBS, L-A treated OVX-BMSCs, normal BMSCs, and Sham rats injected by PBS, L-A treated normal BMSCs. Black open arrows indicate new bone formation and green open arrows indicate bone resorption. Right-Sidedness image Scale bar, 50 μm. (d) Femur bone mass was detected by micro CT, top; and trabecular bone three-dimensional reconstruction in red box, middle, Scale bar, 300 μm. The calceinfluorescent labeling of newly formed bone at different time point, bottom, Scale bar, 100 μm. (e, f) TV/BV and BMD of Trabecular bone after treated 4 and 8 weeks. Greater maximum load of (g) the femur and (h) the fifth lumbar vertebral bodies (LVB) respectively in OVX/Sham group rats treated with kinds BMSCs. Key: n = 6 per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the OVX group. All data are shown as the mean ± s.d.

TRAP/ALP staining. Alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP) are known as marker enzymes for osteoblasts and osteoclasts, respectively. So we used TRAP/ALP staining kit (Walth Chemical USA, Inc.) to examine the state of differentiation of bone cells and the cell distribution in bone tissues by observation of the stained images of osteoblasts and osteoclasts. GMA embedded thin sample sections of non-decalcified bone (2 um thick) were applied to silan coated slides and washed with water. 0.5 mL TRAP staining soln was
applied on each section in a moist chamber at room temperature for 30 minutes. Then adding sufficient distilled water to soak the sections in 3Cplin-staining jars and washing the sections in these jars for 1 min each. Later sufficient amount of 0.1 M AMPD–HCl buffer (pH 9.4) was added to soak the sections in eachCoplin-staining jar for 10 minutes. After that, excessive moisture on the slides was removed and applying 0.5 mL ALP substrate soln on each section for 30 minutes in a moist chamber at room temperature. The same as previously described, add sufficient distilled water to soak the sections in 3Cplin-staining jars and wash the sections in these jars for 1 min each. Finally, add distilled water to soak the sections in a Coplin-staining jar and apply 0.5 mL nuclear staining soln on the sections. After 4–5 seconds, wash the sections by moving them up and soaking in distilled water. The sections were dried on a heater plate at 37°C. As previously described, add sufficient amount of xylene to soak the sections in each Coplin-staining jar. Mount the sections using mounting agents such as Softmount and Malinol and observation was performed.

Transfection of Fasl siRNA. The Fasl siRNA was purchased from Ribobio. The cells were transfected with Fasl siRNA and negative control at final concentrations of 100 nM. The Lipofectamine 2000 (Invitrogen) was used according to the manufacturer’s instructions. In brief, cells were passaged in six-well plates and were 30–50% confluent at the time of transfection. The diluted oligomer was combined with the diluted Lipofectamine 2000 and added to each well. The cells were incubated at 37°C in the incubator for 48 h before further assay.

Statistics. All values are the mean ± SEM. The statistics were performed with GraphPad Prism 5 software using an unpaired Student’s t-test to compare two independent groups or pair for sequential measurements. One-way ANOVA were performed when comparing multiple groups.

1. Smith, D. & Walker, M. Changes in plasma steroids and bone density in Klinefelter’s syndrome. Calcif. Tissue Res. 22 Suppl, 225–8 (1977).
2. Foresta, C. et al. Osteoporosis: now and the future. J. Bone Miner Res. 15, 56–57 (1998).
3. Daniell, H. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology. 58, 101–107 (2001).
4. Hohlbau, A. M., Moe, S. & Marshak-Rothstein, A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191, 1209–1220 (2000).
5. Zhang, Y., Xu, G., Zhang, L., Roberts, A. I. & Shi, Y. Th17 cells undergo Fas-ligand-/FAS-mediated T cell apoptosis. J. Immunol. 181, 190–196 (2008).
6. Akiyama, K. et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 10, 544–55 (2012).
7. Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via caspase-8 cleavage and osteoclast apoptosis. J. Bone Miner Res. 22, 159–70 (2005).
8. Rodrigues, M., Blair, H., Stockdale, L., Griffith, L. & Wells, A. Surface tethered epidermal growth factor protects proliferating and differentiating multipotential stromal cells from FasL-induced apoptosis. Stem Cells. 31, 104–16 (2013).
9. Li, H. et al. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am. J. Physiol.Gastrointest Liver Physiol. 294, G263–75 (2008).
10. Nakamura, T. et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoblasts to regulate osteoclast survival. J. EMBO. 27, 535–45 (2008).
11. Pricola, K. M., Kuhn, N., Haleem-Smith, H., Song, Y. & Tuan, R. Interleukin-6 regulates mesenchymal stem/progenitor cell proliferation and differentiation. Stem Cells. 29, 1804–1816 (2011).
12. Ming, L. G. et al. The prenyl group contributes to activities of phytoestrogens 8-prenylnaringenin in enhancing bone formation and inhibiting bone resorption in vitro. Endocrinology. 154, 1202–14 (2013).
13. Shang, F. et al. The effect of licorichalcone A on cell-aggregates ECM secretion and osteogenic differentiation during bone formation in metaphysical defects in ovariectomized rats. Biomaterials. 35, 2789–97 (2014).

Acknowledgments

This study was supported by the grants from the National Major Scientific Research Program of China (2010CB944800 and 2011CB946700) and the Nature Science Foundation of China (81470710, 31000333, 31301062, 81300718 and 31300140).

Author contributions

M.L., L.W., J.F. and H.P. wrote the main manuscript text; M.L., L.H., Z.L. and Y.W. prepared figures; Z.Y., M.L. and J.Y. designed experimental and data analysis. All authors reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at http://www.nature.com/scientificreports
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Ming, L. et al. Licochalcone A up-regulates of FasL in mesenchymal stem cells to strengthen bone formation and increase bone mass. Sci. Rep. 4, 7209; DOI:10.1038/srep07209 (2014).

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/